Literature DB >> 1727901

Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States.

I M Onorato1, E McCray.   

Abstract

In 1988-1989, surveillance for human immunodeficiency virus (HIV) infection was conducted in 20 clinics providing medical care for patients with suspected and confirmed tuberculosis (TB) in 14 cities. A total of 3077 specimens from consecutive patients were tested for HIV after patient identifiers were removed. The median clinic seroprevalence rate was 3.4%, (range, 0-46.3%). The highest rates were found in the Northeast and Atlantic coastal areas. Rates by clinic were highest for persons born in the United States (median, 11.2%) and in the Caribbean region (Haitians, 36%-40%, and Cubans, 16%). Most HIV-infected patients had pulmonary TB, but HIV infections were more frequent in patients with extrapulmonary TB than in pulmonary TB patients (19.8% vs. 10.2%, P less than .0002). For US-born patients, rates did not differ by race or sex. These serosurveillance data indicate widespread HIV infection among TB patients and have important implications for clinical management of TB patients and for TB and AIDS prevention programs. Testing all HIV-infected persons and all TB patients for dual infection is essential to control the interrelated epidemics of AIDS and TB.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727901     DOI: 10.1093/infdis/165.1.87

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Outcome of pulmonary tuberculosis treatment in the tertiary care setting--Toronto 1992/93. Tuberculosis Treatment Completion Study Group.

Authors:  W Wobeser; L Yuan; M Naus
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

2.  Antimycobacterial activities of novel levofloxacin analogues.

Authors:  K Kawakami; K Namba; M Tanaka; N Matsuhashi; K Sato; M Takemura
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Universal HIV screening at a major metropolitan TB clinic: HIV prevalence and high-risk behaviors among TB patients.

Authors:  S E Weis; B Foresman; P E Cook; K J Matty
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

4.  DNA fingerprinting and phenotyping of Mycobacterium tuberculosis isolates from human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients in Tanzania.

Authors:  Z H Yang; I Mtoni; M Chonde; M Mwasekaga; K Fuursted; D S Askgård; J Bennedsen; P E de Haas; D van Soolingen; J D van Embden
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 5.  New developments in tuberculosis and HIV infection: an opportunity for prevention.

Authors:  J R Curtis; T M Hooton; C M Nolan
Journal:  J Gen Intern Med       Date:  1994-05       Impact factor: 5.128

6.  Tuberculosis among foreign-born residents of southern Florida, 1995.

Authors:  R M Granich; P L Zuber; M McMillan; J D Cobb; J Burr; E D Sfakianaki; M Fussell; N J Binkin
Journal:  Public Health Rep       Date:  1998 Nov-Dec       Impact factor: 2.792

7.  Applications of data from the CDC Family of Surveys.

Authors:  I M Onorato; M Gwinn; T J Dondero
Journal:  Public Health Rep       Date:  1994 Mar-Apr       Impact factor: 2.792

8.  Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects.

Authors:  Michelle B Ryndak; Krishna K Singh; Zhengyu Peng; Susan Zolla-Pazner; Hualin Li; Lu Meng; Suman Laal
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

9.  Extrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993 - 2006.

Authors:  Aaron M Kipp; Jason E Stout; Carol Dukes Hamilton; Annelies Van Rie
Journal:  BMC Public Health       Date:  2008-04-04       Impact factor: 3.295

Review 10.  Mycobacterium tuberculosis Primary Infection and Dissemination: A Critical Role for Alveolar Epithelial Cells.

Authors:  Michelle B Ryndak; Suman Laal
Journal:  Front Cell Infect Microbiol       Date:  2019-08-21       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.